Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).
- Authors
- Lavie, D[Lavie, David]; Ozcan, M[Ozcan, Muhit]; Paszkiewicz-Kozik, E[Paszkiewicz-Kozik, Ewa]; Barca, EG[Barca, Eva Gonzalez]; Kim, TM[Kim, Tae Min]; Puccini, B[Puccini, Benedetta]; Wang, SR[Wang, Siruo]; Yusuf, R[Yusuf, Rushdia]; Marinello, P[Marinello, Patricia]; Kim, WS[Kim, Won Seog]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.